Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/28444| Title: | Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. | Austin Authors: | Lickliter, Jason D;Voskoboynik, Mark;Mileshkin, Linda;Gan, Hui K ;Kichenadasse, Ganessan;Zhang, Kathy;Zhang, Maggie;Tang, Zhiyu;Millward, Michael | Affiliation: | Medicine (University of Melbourne) Olivia Newton-John Cancer Wellness and Research Centre Peter MacCallum Cancer Centre-East Melbourne, East Melbourne, VIC, Australia La Trobe University School of Cancer Medicine, Heidelberg, VIC, Australia Central Clinical School, Monash University, Melbourne, VIC, Australia Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, SA, Australia Linear Clinical Research & University of Western Australia, Nedlands, WA, Australia BeiGene USA, Inc., San Mateo, CA, USA Nucleus Network, Melbourne, VIC, Australia |
Issue Date: | Feb-2022 | Date: | 2021 | Publication information: | British Journal of Cancer 2021; 126(2): 310. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/28444 | DOI: | 10.1038/s41416-021-01671-9 | ORCID: | 0000-0001-9923-5149 0000-0002-1744-1617 0000-0001-7319-8546 |
Journal: | British Journal of Cancer | PubMed URL: | 34931042 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/34931042/ | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.